ARTEMIS MRI Fusion Biopsy: Elevating Prostate Diagnostics in the U.S. Healthcare System
A New Standard in Precision Urology In the constantly evolving field of urology, few advancements have matched the impact of MRI fusion biopsy technology. As prostate cancer continues to affect 1 in 8 men in the United States during their lifetime, healthcare professionals are under increasing pressure to deliver faster, more accurate diagnostics while minimizing invasiveness and cost. ARTEMIS , developed by Innomedicus, is a standout response to this need. The ARTEMIS MRI Fusion Biopsy System seamlessly integrates MRI and ultrasound images into a single, guided biopsy procedure that raises the bar for precision and reliability in prostate cancer detection. Tailored to meet the demands of the U.S. market, ARTEMIS is already redefining how clinicians approach prostate diagnostics. Designed for Accuracy, Built for Efficiency Real-Time MRI/Ultrasound Fusion Traditional TRUS biopsies often miss up to 30% of clinically significant prostate cancers due to their blind sampling approa...